This study is currently not recruiting participants.

Losartan for the Treatment of Pediatric NAFLD (STOP-NAFLD): A Phase 2 Randomized Placebo-Controlled Clinical Trial

Investigating an Investigational Medication for Pediatric NAFLD

Not Recruiting
100 years or below
All
Phase N/A

Brief description of study.

This is a multicenter, randomized, double masked, placebo-controlled, parallel treatment groups phase 2 trial of losartan for pediatric NAFLD.

Detailed description of study

This is a multicenter, randomized, double masked, placebo-controlled, parallel treatment groups phase 2 trial of losartan for pediatric NAFLD.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Pediatric NAFLD
  • Age: 100 years or below
  • Gender: All

This study investigates pediatric non-alcoholic fatty liver disease (NAFLD), which is a condition where fat builds up in the liver of children without alcohol use. The purpose of this study is to explore the effects of an investigational medication on pediatric NAFLD.

Participants in the study will be randomly assigned to different study arms. Some will receive the investigational medication, while others will receive a placebo. A placebo is an inactive substance that looks like the investigational medicine but does not contain any medicine.

  • Who can participate: Eligible participants are children aged 6 to 17 years diagnosed with non-alcoholic fatty liver disease (NAFLD).
  • Study details: Participants will be randomly assigned to receive either the investigational medication or a placebo. A placebo is an inactive substance that looks like the investigational medicine but does not contain any medicine.
Updated on 19 Feb 2024. Study ID: 1805733931

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Connect with the study team